Literature DB >> 18791348

Biochemical markers in glucocorticoid-induced osteoporosis.

S Minisola1, R Del Fiacco, S Piemonte, M Iorio, M L Mascia, F Fidanza, C Cipriani, I Raso, M L Porfiri, C M Francucci, E D'Erasmo, E Romagnoli.   

Abstract

Following the introduction of corticosteroids as therapeutic agents in the 1950s, their use has been expanded so that today glucocorticoids are widely used. There are few studies in the literature directly aimed at describing the changes of bone markers following glucocorticoid administration. The interpretation of some of these investigations may be hampered by a number of confounding factors, whose influence is not always taken into consideration. In general, the effects of glucocorticoid administration are represented by a reduction in bone formation markers (particularly considering serum osteocalcin levels) and a trend to an increase or no change in bone resorption markers. The inconsistency of this last finding may be related to the time at which the observation is carried out and to the marker employed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18791348

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  6 in total

1.  Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid.

Authors:  H Kaji; M Yamauchi; T Yamaguchi; T Sugimoto
Journal:  Osteoporos Int       Date:  2009-11-14       Impact factor: 4.507

2.  Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study.

Authors:  Stine Marit Moen; Elisabeth Gulowsen Celius; Leiv Sandvik; Magritt Brustad; Lars Nordsletten; Erik Fink Eriksen; Trygve Holmøy
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

3.  Distribution of serum βCTX in a population-based study of postmenopausal women taking into account different anti-osteoporotic therapies (the FRODOS Cohort).

Authors:  Eduardo Kanterewicz; Pilar Peris; Emma Puigoriol; Aina Yáñez; Pau Rosique; Luis Del Rio
Journal:  J Bone Miner Metab       Date:  2012-12-08       Impact factor: 2.626

4.  Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis.

Authors:  P Farahmand; F Marin; F Hawkins; R Möricke; J D Ringe; C-C Glüer; N Papaioannou; S Minisola; G Martínez; J M Nolla; C Niedhart; N Guañabens; R Nuti; E Martín-Mola; F Thomasius; J Peña; C Graeff; G Kapetanos; H Petto; A Gentzel; A Reisinger; P K Zysset
Journal:  Osteoporos Int       Date:  2013-06-06       Impact factor: 4.507

Review 5.  Long-term therapy in COPD: any evidence of adverse effect on bone?

Authors:  Arnulf Langhammer; Siri Forsmo; Unni Syversen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19

6.  Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study.

Authors:  Ki-Seong Eom; Seok Jin Kim; Je-Jung Lee; Cheolwon Suh; Jin Seok Kim; Sung-Soo Yoon; Byung Soo Kim; Hye Jin Kang; Young Jin Choi; Chul Soo Kim; Yang Soo Kim; Jae-Yong Kwak; Yoo Jin Kim; Young Don Joo; Yeung-Chul Mun; Deog Yeon Jo; Joon Seong Park; Chi-Young Park; Sung-Hyun Kim; Chang-Ki Min
Journal:  Biomed Res Int       Date:  2014-06-23       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.